The Intellectual Property Owners Association (IPO) will offer a one-hour webinar entitled "Who Will 'Dance' Now? Biosimilars After Amgen v. Sandoz" on July 12, 2017 from 2:00 to 3:00 pm (ET).  Elaine Blais of Goodwin Procter LLP, Brian Slater of Kramer Levin Naftalis & Frankel LLP, and Bruce Wexler of Paul Hastings LLP will give their views on what lies ahead regarding such questions as:

• Will the "patent dance" be essentially mandatory under state law?
• Will availability of an injunction vary by state, perhaps triggering important venue issues?
• When would a biosimilar maker choose the patent dance even if it is not mandatory?
• How soon can a biosimilar manufacturer give notice of commercial marketing?
• Can it be done before filing for FDA approval?

The registration fee for the webinar is $135 (government and academic rates are available upon request).  Those interested in registering for the webinar can do so here.